PDCD1 and neoplasm: The PD-1 knockout CAR-T cells exhibited stronger cytokine production and cytotoxicity toward PD-1-positive tumor cells and performed better in terms of tumor control and relapse prevention in vivo than conventional CAR-T cells with or without anti-PD-1 antibody treatment [164].